

Why carry out this study?

- Treatment non-adherence is a complex problem encountered in all therapy areas, particularly in chronic diseases such as psoriasis vulgaris
- Topical therapies may be perceived as messy, inconvenient and time consuming, posing an additional challenge to adherence
- To improve patient experience with fixed combination Cal/BD topical suspension, we developed an applicator delivery system that caters to some unmet needs of psoriasis patients

What was learned from the study?

- The Applicator delivers a consistently accurate dose, allows for targeted and precise application to body and scalp psoriasis plaques, and offers a ‘no touch’ option for patients
- For some patients with psoriasis vulgaris, the Applicator has potential to provide greater control over daily psoriasis management, which could promote long-term treatment adherence

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by LEO Pharma. Medical writing assistance for this study was provided by Catherine Risebro from Mudskipper Business Ltd and funded by LEO Pharma. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).